Like Eidetics

announced 5/7/2008 via PR Newswire

Quintiles Transnational Corp., will acquire Eidetics

synopsis: Quintiles Transnational Corp. announced that it has signed an agreement to acquire Eidetics, a privately held decision-analytics and market research consulting firm located in Boston as part of its expanding Quintiles Consulting business.
buyer: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the only fully integrated bio and pharmaceutical services provider offering clinical, commercial, consulting and capital solutions. Our 23,000 employees in more than 50 countries have helped develop or commercialize all of the top 30 best-selling drugs. "
target: Eidetics
Eidetics is being acquired by Quintiles. A market research and consulting company serving the world's leading pharmaceutical, biotechnology, and medical device companies. Headquartered in Boston, we have extensive international resources to address the global nature of today's marketing challenges.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/2/2018 via PR Newswire

ZS Associates, purchased BASES Pharmaceutical Forecasting from The Nielsen Company, Inc.

synopsis: ZS announced it has acquired the assets of BASES Pharmaceutical Forecasting from Nielsen. The BASES Pharmaceutical Forecasting assets include launch product and direct-to-consumer forecasting tools and proprietary normative databases for pharmaceutical brands.
buyer: ZS Associates
ZS Associates is a global management consulting firm specializing in sales and marketing strategy, operations and execution. Founded in 1983, ZS has grown into a firm of 500 professionals delivering expertise across much of the sales and marketing spectrum. "
seller: The Nielsen Company, Inc. (NLSN:$6,465.00)
The BASES Pharmaceutical Forecasting assets include launch product and direct-to-consumer forecasting tools and proprietary normative databases for pharmaceutical brands.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 3/8/2012 via PR Newswire

Diversified Agency Services, will acquire Medical Collective Intelligence Co. Ltd.

synopsis: Diversified Agency Services announced an agreement with ITOCHU Corporation and a number of venture capital funds to acquire a majority stake in Medical Collective Intelligence Co. Ltd., a highly respected Japanese online medical communications agency.
buyer parent: Omnicom Group Inc.
buyer: Diversified Agency Services
Diversified Agency Services (DAS), a division of Omnicom Group Inc., manages Omnicom's holdings in a variety of marketing disciplines. DAS includes more than 190 companies, which operate through a combination of networks and regional organizations. "
target parent: Itochu Corporation
target: Medical Collective Intelligence Co. Ltd.
Medical Collective Intelligence Co. Ltd. ("MCI") is a highly respected and well-known Japanese online medical communications agency. Based in Tokyo, MCI operates a Marketing Research division and a Detailing Solutions division, both focused on the healthcare industry.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/24/2012 via BusinessWire

IMS Health Incorporated, acquired PharmARC Analytic Solutions Pvt. Ltd.

synopsis: IMS Health has acquired PharmARC, an India-based company specializing in commercial analytics and services for the life sciences industry. The acquisition adds significant scale to a world-class services delivery platform, strengthens IMS’s business process outsourcing capabilities.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is the leading provider of information services for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, analytics, and consulting platforms to help clients better understand the value of medicines. "
target: PharmARC Analytic Solutions Pvt. Ltd.
PharmARC is a leading provider of analytic solutions for the efficient commercialization of drugs and medical products. The firm’s analytics and services enable its life sciences customers to make informed decisions related to their sales and marketing strategies and implementation.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 1/17/2012 via PR Newswire

Campbell Alliance Group, Inc., will purchase Promotional and Medical Audit Businesses from SDI Health LLC

synopsis: inVentiv Health, Inc. has entered into a definitive agreement to acquire certain promotional and medical audit businesses of SDI Health, which IMS Health has committed to divest in connection with obtaining regulatory approval of its acquisition of SDI.
buyer parent: Thomas H. Lee Partners, L.P.
buyer: Campbell Alliance Group, Inc.
Campbell Alliance is the Consulting business segment of inVentiv Health, a leading global provider of best-in-class clinical, commercial, and consulting services to companies seeking to accelerate performance. "
seller parent: TPG Capital
seller: SDI Health LLC
SDI Health is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/1/2011 via BNC Analysis

IMS Health Incorporated, acquired SDI Health LLC

synopsis: IMS Health has completed its acquisition of SDI, a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market.
buyer parent: TPG Capital
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is the world’s leading provider of market intelligence to the pharmaceutical and healthcare industries. IMS offers leading-edge market intelligence products and services that are integral to clients’ day-to-day operations. "
target parent: LLR Partners
target: SDI Health LLC
SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, and medical device companies, enabling them to better understand the healthcare market.
price ($mm)
$340
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 8/2/2010 via BNC Analysis

United Drug plc, acquired InforMed Direct

synopsis: United Drug Plc, an Ireland-based healthcare services provider, has acquired the entire share capital of InforMed Direct Plc, a UK-based healthcare communications and market research agency, for a consideration of GBP11.4 million in cash.
buyer: United Drug plc (LSE:UDG:$1,298.52)
United Drug is a leading international healthcare services provider, employing 6,000 people in 35 businesses across Europe and the US. United Drug operates through 4 divisions. United Drug is a provider of services to pharmaceutical retailers and manufacturers. "
target: InforMed Direct
InforMed offers healthcare communications at every stage of the product lifecycle – from development and consultancy to tactical delivery. Its market research and business analysis division delivers quant and qual research, as well as forecasting and market simulation models.
price ($mm)
$18
rev ($mm)
$16
EBITDA ($mm)
EV / rev
1.7x
EV / EBITDA
closed 1/19/2010 via PR Newswire

Decision Resources, Inc., acquired BioTrends Research Group, Inc.

synopsis: Decision Resources, Inc., one of the world's leading research and advisory firms focusing on healthcare insights and analysis, announced that it acquired BioTrends Research Group, the leader in providing specialized, syndicated market research in clinically complex, small to mid-size pharmaceutical markets.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: BioTrends Research Group, Inc.
BioTrends Research Group, Inc. provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/19/2007 via PR Newswire

Decision Resources, Inc., acquired Arlington Medical Resources Inc.

synopsis: Berkery Noyes, the leading independent investment bank serving the media, information and technology markets, announces that it represented Arlington Medical Resources, Inc. in its sale to Decision Resources, Inc., a portfolio company of Providence Equity Partners, Inc. Terms of the transaction were not disclosed.
buyer parent: Providence Equity Partners Inc.
buyer: Decision Resources, Inc.
Decision Resources, Inc. is a world leader in research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources consists of the medical technology business unit and the biopharma business unit. "
target: Arlington Medical Resources Inc.
AMR is a privately held pharmaceutical market research firm headquartered in suburban Philadelphia. We have been serving the market research needs of the pharmaceutical & diagnostic imaging industries since 1988.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/22/2004 via PR Newswire

Ventiv Health, acquired HHI Clinical Research & Statistical Services, L.L.C.

synopsis: Ventiv Health, Inc. VTIV, a leading provider of late-stage clinical, sales, marketing and compliance services to pharmaceutical and biotech organizations, today announced that it has successfully completed the acquisition of HHI Clinical & Statistical Research Services, L.L.C.
buyer: Ventiv Health
inVentiv Health, Inc. is the leading provider of commercialization and complementary services to the global pharmaceutical, life sciences and biotechnology industries. inVentiv delivers its customized clinical, sales, marketing and communications solutions. "
target: HHI Clinical Research & Statistical Services, L.L.C.
HHI Clinical Research & Statistical Services, L.L.C. is a focused clinical service provider managing statistical analysis and data management functions for pharmaceutical and biotechnology companies. HHI's services include data support, programming, statistical analysis and report writing. HHI has
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/16/2004 via PR Newswire

Thomson Scientific & Healthcare, acquired Newport Strategies, Inc.

synopsis: The Thomson Corporation announced that it has acquired Newport Strategies, Inc., a leading provider of competitive intelligence for the pharmaceutical industry. Newport Strategies will become part of the scientific business within the Thomson Scientific and Healthcare market group.
buyer parent: The Thomson Corporation
buyer: Thomson Scientific & Healthcare (:$964.58)
Thomson Scientific & Healthcare provides integrated information solutions to researchers and librarians, physicians and pharmacists, and other professionals worldwide. "
target: Newport Strategies, Inc.
Newport develops and markets cutting-edge systems that deliver the earliest and most reliable source of global intelligence on competition for launched pharmaceutical products. Innovator, generic and specialty pharmaceutical companies worldwide use Newport's systems and expert confidential consulti
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 1/26/2005 via PR Newswire

Greenfield Online, Inc., acquired Rapidata.net, Inc.

synopsis: Greenfield Online, Inc SRVY, a leading provider of Internet survey solutions to marketing research and consulting companies, today announced it has completed the acquisition of Rapidata.net, Inc., a privately-held North Carolina corporation, for $5.5 million in cash, subject to certain post closing adjustments.
buyer: Greenfield Online, Inc. (SRVY:$0.00)
Greenfield Online, Inc. is a global interactive media and services company that collects consumer attitudes about products and services, enabling consumers to reach informed purchasing decisions about the products and services they want to buy; and helping companies better understand their customer."
target: Rapidata.net, Inc.
Founded fifteen years ago by research pharmacist and professor David P. Lipson, R.PH., Ph.D., Rapidata.net connects pharmaceutical market researchers to healthcare providers and their patients. This connection allows pharmaceutical market researchers to learn more about the prescription medications
price ($mm)
$5.50
rev ($mm)
$2
EBITDA ($mm)
EV / rev
2.6x
EV / EBITDA
closed 6/25/2012 via PR Newswire

McCann Health, acquired Double Helix

synopsis: McCann Health announced the acquisition of Double Helix. Double Helix is a leading, global provider of Market Research and Market Access services to the pharmaceutical and medical device industries. Dr. Wayne Phillips, who founded and runs Double Helix, will continue as CEO of Double Helix, reporting to John Cahill, CEO of McCann Health.
buyer parent: Interpublic Group of Companies, Inc.
buyer: McCann Health
Comprising the world's most connected health and wellness experts, McCann Health is the most awarded professional and consumer health communications network with the largest international expertise spanning 35 countries and 61 offices. "
target: Double Helix
Double Helix is an independent healthcare consultancy with headquarters in London and offices in the US and Singapore. Established in 1995, they have been providing pharmaceutical, biotech and medical device clients of all sizes with the knowledge to evolve their brands and businesses.
price ($mm)
$55
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/14/2009 via BusinessWire

Majestic Research, LLC, acquired Rood Research, Inc.

synopsis: Majestic Research, a global, independent equity research company and a pioneer in data driven analysis, announced its acquisition of New York-based Rood Research – a leading provider of healthcare market research.
buyer: Majestic Research, LLC
Since its inception in 2002, Majestic Research has revolutionized the financial research business with our innovative proprietary methods and tools for accessing real-time data. "
target: Rood Research, Inc.
In the past 15 years, Rood Research has become a leader in providing healthcare research to some of the top pharmaceutical and biotech companies in the world.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/30/2008 via BusinessWire

Surveillance Data, Inc., acquired Verispan, LLC

synopsis: SDI, the leader in innovative healthcare analytics, has acquired Verispan, a top provider of healthcare information and services. The acquisition creates the healthcare industry’s most comprehensive de-identified longitudinal database.
buyer parent: LLR Partners
buyer: Surveillance Data, Inc.
SDI provides a wide range of healthcare data and market research to pharmaceutical, consumer products, and healthcare-related companies. Since 1981, SDI's mission has been to provide healthcare data products with high business relevance as well as the means and know-how to put this data into action."
target: Verispan, LLC
Verispan provides a broad array of information products and services to virtually all of the top 50 pharmaceutical companies and the healthcare industry in general, including sales targeting and compensation products; market research audits; healthcare profiles; and direct mail, among many others.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/16/2018 via Company Press Release

Vestar Capital Partners, will acquire Information Resources, Inc.

synopsis: Vestar Capital Partners, a private equity firm, will lead a new investment in Information Resources, Inc., a leading provider of big data, predictive analytics and forward-looking insights. Jeffrey Ansell, a Vestar Senior Advisor, will serve as Chairman of IRI. New Mountain and other existing investors are retaining a meaningful investment in IRI.
buyer: Vestar Capital Partners
Vestar Capital Partners (VCP) is a private equity firm specializing in management buyouts and growth capital investments. VCP collaborates with management teams and private owners to build long- term enterprise value, with a focus on Consumer, Healthcare, and Business Services & Industrial Products."
target parent: New Mountain Capital, LLC
target: Information Resources, Inc.
Information Resources, Inc. is a leading provider of big data, predictive analytics and forward-looking insights that help CPG companies, OTC health care organizations, retailers, financial services and media companies grow their businesses.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/1/2018 via Company Press Release

BioInformatics Inc., acquired Kalorama Information

synopsis: BioInformatics Inc., the premier research and advisory company serving the life science industry, has acquired Kalorama Information from MarketResearch. Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics, imaging, biotechnology, healthcare, medical devices, and pharmaceuticals.
buyer: BioInformatics Inc.
BioInformatics Inc. is the leading research and advisory firm serving the life science, diagnostic and analytical instrument industries. Their expertise includes assessing the size and attractiveness of markets, optimizing product configurations and pricing and validating corporate acquisitions. "
target parent: MarketResearch.com, Inc.
target: Kalorama Information
Kalorama Information is a leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), imaging, biotechnology, healthcare, medical devices, and pharmaceuticals. Kalorama only publishes in healthcare.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/6/2017 via Company Press Release

The Access Group, acquired Health Strategies Group

synopsis: Water Street Healthcare Partners, through its subsidiary, The Access Group, has acquired Health Strategies Group. Health Strategies Group is the leader in market access intelligence and customized research for pharmaceutical and biotech professionals. It dissects trends and identifies opportunities to help companies optimize their product access.
buyer parent: Water Street Healthcare Partners
buyer: The Access Group
The Access Group offers a breadth of services to clients, from traditional “block-and-tackle” launch execution tactics to in-depth market assessments. The company is dedicated to complete product life cycle management, creating brand solutions that drive demand across multiple stakeholder channels. "
target: Health Strategies Group
Health Strategies Group offers a dedicated team of research leaders committed to dissecting the trends, identifying customer needs, and pinpointing the barriers and opportunities for biopharma within the evolving health care environment.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/15/2015 via PR Newswire

Insignia Capital Group, acquired Metanexgen, Inc.

synopsis: Insignia Capital Group announced the acquisition of metanexgen from DFW Capital Partners. Based in Bensalem, PA, metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
buyer: Insignia Capital Group
Insignia Capital is a private equity firm working with lower-middle market companies. Insignia Capital works with a wide variety of companies but their specialty is consumer, business services and healthcare. "
target parent: DFW Capital Partners
target: Metanexgen, Inc.
Metanexgen is a provider of technology-enabled multi-channel marketing solutions that allow pharmaceutical, biotechnology and medical device brands to effectively market their products to healthcare practitioners.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 11/12/2014 via Company Press Release

Everyday Health, Inc., will acquire DoctorDirectory.com

synopsis: Everyday Health signed a definitive agreement to acquire DoctorDirectory. Based in North Carolina, DoctorDirectory provides pharmaceutical companies with multi-channel marketing services that target healthcare professionals. DoctorDirectory.com, Inc. also operates as an online directory for finding a doctor by specialty.
buyer: Everyday Health, Inc. (EVDY:$253.92)
Everyday Health, Inc. is a provider of digital health and wellness solutions. They attract consumers and healthcare professionals to their health and wellness properties, and utilize their data and analytics to deliver personalized content experiences and marketing and engagement solutions. "
target: DoctorDirectory.com
DoctorDirectory.com, Inc. operates as an online directory for finding a doctor by specialty. They also provide Healthcare Professionals the opportunity to participate in Market Research and other programs that help shape the healthcare industry.
price ($mm)
$65
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/7/2008 via PR Newswire

Quintiles Transnational Corp., will acquire Eidetics

synopsis: Quintiles Transnational Corp. announced that it has signed an agreement to acquire Eidetics, a privately held decision-analytics and market research consulting firm located in Boston as part of its expanding Quintiles Consulting business.
buyer: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the only fully integrated bio and pharmaceutical services provider offering clinical, commercial, consulting and capital solutions. Our 23,000 employees in more than 50 countries have helped develop or commercialize all of the top 30 best-selling drugs. "
target: Eidetics
Eidetics is being acquired by Quintiles. A market research and consulting company serving the world's leading pharmaceutical, biotechnology, and medical device companies. Headquartered in Boston, we have extensive international resources to address the global nature of today's marketing challenges.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2017 via BusinessWire

eMids Technologies, acquired Encore Health Resources

synopsis: emids, a rapidly growing global provider of IT services and solutions for the healthcare and life sciences industries, announced the acquisition of Encore Health Resources, a leading healthcare information analytics company focused on value-based care and electronic health records for providers.
buyer: eMids Technologies
emids is a premier provider of healthcare IT services and solutions. emids enables healthcare entities to achieve accessible, affordable and high-quality care by providing custom application and data solutions. "
target parent: QuintilesIMS
target: Encore Health Resources
Encore Health Resources is a leading healthcare information analytics company focused on value-based care and electronic health records for providers.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/1/2014 via BusinessWire

Quintiles Transnational Corp., acquired Encore Health Resources

synopsis: Quintiles announced that it has completed the acquisition of Encore Health Resources, a leader in the health-information analytics and technology consulting services industry focused on healthcare providers.
buyer: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development and commercial outsourcing services with a network of more than 29,000 employees conducting business in approximately 100 countries. "
target: Encore Health Resources
Encore Health Resources provides world-class industry experts to the healthcare market who have specialized knowledge of the industry’s major clinical and business applications.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/19/2011 via BusinessWire

Quintiles Transnational Corp., acquired VCG

synopsis: Quintiles announced the acquisition of VCG & Associates and VCG BIO ("VCG"), based in Holliston, Mass., and Cave Creek, Ariz., respectively. The addition of VCG strengthens Quintiles’ comprehensive commercial services in sales and brand solutions, product solutions, product distribution and market access.
buyer: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. "
target: VCG
VCG develops strategic healthcare marketing initiatives to address the challenges surrounding U.S. pharmaceutical market entry. It focuses on biopharma companies that need supplemental resources to maximize commercial opportunities.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 5/7/2008 via PR Newswire

Quintiles Transnational Corp., will acquire Eidetics

synopsis: Quintiles Transnational Corp. announced that it has signed an agreement to acquire Eidetics, a privately held decision-analytics and market research consulting firm located in Boston as part of its expanding Quintiles Consulting business.
buyer: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the only fully integrated bio and pharmaceutical services provider offering clinical, commercial, consulting and capital solutions. Our 23,000 employees in more than 50 countries have helped develop or commercialize all of the top 30 best-selling drugs. "
target: Eidetics
Eidetics is being acquired by Quintiles. A market research and consulting company serving the world's leading pharmaceutical, biotechnology, and medical device companies. Headquartered in Boston, we have extensive international resources to address the global nature of today's marketing challenges.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 9/25/2017 via BusinessWire

Konica Minolta, Inc., will acquire Invicro, LLC

synopsis: Konica Minolta, Inc. and Boston-based Invicro LLC announced that they have concluded an agreement whereby Konica Minolta will acquire Invicro, a leading provider of imaging services and software for research and drug development.
buyer: Konica Minolta, Inc. (TSE:4902:$8,793.96)
Konica Minolta, Inc. is a Japanese technology company headquartered in Tokyo. The company manufactures business and industrial imaging products, including copiers, laser printers, multi-functional peripherals (MFPs) and digital print systems for the production printing market. "
target: Invicro, LLC
Invicro is a leading provider of imaging services and software for research and drug development. Headquartered in Boston, Massachusetts, Invicro LLC was founded in 2008 with the mission of improving the role and function of imaging in drug discovery and development across all therapeutic areas.
price ($mm)
rev ($mm)
$106
EBITDA ($mm)
$17
EV / rev
0.0x
EV / EBITDA
0.0x
closed 8/16/2017 via BusinessWire

Evotec BioSystems GmbH, acquired Aptuit, Inc.

synopsis: Evotec announced that it has successfully completed the acquisition of Aptuit, a partner research organisation for integrated outsourced drug discovery and development solutions. This acquisition adds considerable business opportunities to further accelerate Evotec's long-term strategy to be the industry partner of choice for external innovation.
buyer: Evotec BioSystems GmbH (XTRA:EVT:$226.46)
Founded in Hamburg Germany, Evotec BioSystems GmbH is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. "
target parent: Welsh, Carson, Anderson & Stowe
target: Aptuit, Inc.
Aptuit, Inc. (formerly Global Pharmaceutical Development, Inc.) is an emerging company focused on streamlining and supporting the drug development process for biotechnology and pharmaceutical innovators.
price ($mm)
$300
rev ($mm)
$93
EBITDA ($mm)
$12
EV / rev
3.2x
EV / EBITDA
25.8x
announced 6/20/2017 via Company Press Release

Pamplona Capital Management LLP, will acquire PAREXEL International Corporation

synopsis: Pamplona Capital Management, LLP has entered into a definitive agreement to acquire all of the outstanding shares of PAREXEL International Corporation, a leading global biopharmaceutical services provider. PAREXEL provides a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services.
buyer: Pamplona Capital Management LLP
Pamplona Capital Management is a London, New York, and Boston-based specialist investment manager established in 2005 that provides an alternative investment platform across private equity, fund of hedge funds, and single-manager hedge fund investments. "
target: PAREXEL International Corporation (PRXL:$1,939.36)
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries.
price ($mm)[EV]
$4,508 [$4,923]
rev ($mm)
$2,097
EBITDA ($mm)
$343
EV / rev
2.4x
EV / EBITDA
14.6x
announced 5/10/2017 via BNC Analysis

inVentiv Health, Inc. will be merged with INC Research, Inc.,

synopsis: INC Research Holdings, Inc., a leading global Phase I-IV Contract Research Organization ("CRO"), and inVentiv Health, Inc., a leading, global CRO and Contract Commercial Organization will merge. INC Research shareholders will own approximately 53 percent and inVentiv shareholders will own approximately 47 percent of the merged entity.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. "
target parent: Thomas H. Lee Partners, L.P.
target: inVentiv Health, Inc.
inVentiv Health is a global professional services organization designed to help the biopharmaceutical industry accelerate the delivery of much-needed therapies to market. Their Clinical Research Organization (CRO) and Contract Commercial Organization (CCO) offer a differentiated suite of services.
price ($mm)[EV]
$2,453 [$4,552]
rev ($mm)
$2,156
EBITDA ($mm)
$306
EV / rev
2.1x
EV / EBITDA
14.9x
closed 10/3/2016 via BusinessWire

Quintiles Transnational Corp. merged with IMS Health Incorporated,

synopsis: Quintiles IMS Holdings, Inc. announced that it has successfully completed its merger of equals transaction between IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. The merger creates a leading information and tech-enabled global healthcare service provider, and a full suite of end-to-end clinical and commercial offerings.
buyer: IMS Health Incorporated (NYSE:IQV:$10,412.00)
IMS Health is a leading global information and technology services company providing clients in the healthcare industry with end-to-end solutions to measure and improve their performance. They connect configurable SaaS applications to complex healthcare data in the IMS One™ cloud platform. "
target: Quintiles Transnational Corp. (Q:$4,497.17)
Quintiles is the world’s largest provider of biopharmaceutical development services and commercial outsourcing services. They help customers navigate the increasingly complex healthcare environment to improve efficiency and to deliver better healthcare outcomes.
price ($mm)
$8,750
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 11/6/2009 via BusinessWire

PPD, Inc., acquired Excel PharmaStudies Inc.

synopsis: PPD, Inc. announced it has completed its acquisition of Excel PharmaStudies, Inc., one of the largest contract research organizations in China. The acquisition strengthens PPD’s full range of drug development services in the country and positions it to capitalize on the tremendous growth of the outsourcing market in Asia Pacific.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: Excel PharmaStudies Inc.
Excel PharmaStudies, Inc. is a full-service provider of clinical research, registration, biometrics, and training and consultation services. Excel is the leading CRO in China and operates 22 offices worldwide, with more than 300 staff members.
price ($mm)
$16
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 7/17/2009 via PR Newswire

Pierrel SpA, purchased US Operations from Encorium Group Inc.

synopsis: Encorium Group, Inc., a full service multinational clinical research organization, announced that is has completed the previously announced sale of the Company's U.S. business to Pierrel Research USA, Inc., a wholly-owned subsidiary of Pierrel SpA, an international contract research organization listed on Milano's Stock Exchange.
buyer: Pierrel SpA (PIELF:$0.00)
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use. "
seller: Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
price ($mm)[EV]
$0.08 [$2.58]
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 4/8/2009 via PR Newswire

Next Fuel, Inc., will acquire Clinical Trials of the Americas, Inc.

synopsis: Clinical Trials of America Inc. announced that it has entered into a binding letter of intent to sell shares equal to approximately 75% of its issued and outstanding shares to Next Fuel Inc., a developer of a proprietary "On Demand" Hydrogen Generation System.
buyer: Next Fuel, Inc.
Next Fuel Inc. is a developer of a proprietary "On Demand" Hydrogen Generation System that is used as fuel for Fuel Cells which produce electricity. "
target: Clinical Trials of the Americas, Inc.
Clinical Trials of the Americas, Inc. provides clinical trial investigator services in dedicated sites throughout the Americas. Initially, we intend to introduce our services in Central America.
price ($mm)
$0.29*
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/2/2009 via PR Newswire

ASG, Inc., acquired Ockham Development Group, Inc.

synopsis: ASG, Inc. a high-quality functional outsourcing and specialty staffing services group based in Cary, North Carolina - has acquired neighboring Ockham Development Group, Inc., a full-service contract research organization.
buyer: ASG, Inc.
ASG provides high-quality functional outsourcing and specialty staffing services to CROs, pharmaceutical, biotech and medical device companies that require clinical operations, GCP, GLP or GMP auditing, data management, statistical programming, biostatistics and medical writing solutions. "
target: Ockham Development Group, Inc.
Ockham Development Group Inc. is a privately held contract research organization headquartered in Cary, North Carolina.
price ($mm)
rev ($mm)
$12
EBITDA ($mm)
EV / rev
0.0x
EV / EBITDA
closed 4/22/2009 via BusinessWire

PPD, Inc., acquired AbCRO, Inc.

synopsis: PPD, Inc. announced that it has completed the acquisition of AbC.R.O., Inc., a Bulgarian contract research organization. The acquisition strengthens PPD’s ability to provide a broad range of clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs services to its growing client base in the Balkans.
buyer: PPD, Inc.
PPD is a leading global contract research organization (CRO) providing discovery, development and post-approval services as well as compound partnering programs. PPD's clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. "
target: AbCRO, Inc.
AbCRO provides a full range of Phase II-IV clinical services, including clinical trial management and monitoring, patient recruitment, site identification and regulatory affairs.
price ($mm)
$36
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 3/20/2009 via PR Newswire

PharmaNet Development Group, Inc. merged with JLL Partners,

synopsis: JLL Partners, a leading private equity investment fund, and PharmaNet Development Group, Inc., a leading provider of clinical development services, announced the successful completion of the tender offer by JLL PharmaNet Holdings, LLC.
buyer: JLL Partners
Founded in 1988, JLL Partners is among the leading private equity investment firms in the country. Since inception, we have managed a series of private equity funds aggregating approximately $4 billion in committed capital. "
target: PharmaNet Development Group, Inc.
PharmaNet Development Group, Inc. is a leader in outsourced clinical development that offers clinical-development solutions including early and late stage consulting services, Phase I clinical studies and bioanalytical analyses, and Phase II, III and IV clinical development programs.
price ($mm)[EV]
$101 [$186]
rev ($mm)
$451
EBITDA ($mm)
$26
EV / rev
0.4x
EV / EBITDA
7.1x
closed 1/27/2009 via BusinessWire

Altarum Institute, acquired KAI Research, Inc.

synopsis: Altarum Institute, a non-profit health systems research and consulting organization, has purchased Rockville, Maryland-based KAI Research, Inc. (KAI). KAI provides innovative, cost-effective and practical support to the pharmaceutical and biotech industry, academic institutions and the National Institutes of Health.
buyer: Altarum Institute
Altarum Institute is a nonprofit health systems research and consulting organization serving government and private-sector clients. "
target: KAI Research, Inc.
KAI Research provides innovative, cost-effective and practical support to the pharmaceutical and biotech industries. KAI currently supports pharmaco-vigilance activities for over 90 marketed drugs and is providing safety surveillance for dozens of ongoing clinical trials.
price ($mm)
$7.55
rev ($mm)
$10
EBITDA ($mm)
EV / rev
0.8x
EV / EBITDA
closed 3/13/2009 via BNC Analysis

Premier Research Group, acquired Pivotal Research Centers, LLC

synopsis: PHC, Inc. d/b/a Pioneer Behavioral Health, a leading provider of inpatient and outpatient behavioral health services, announced Premier Research Arizona, LLC, a unit of Premier Research Group PLC, has signed a purchase agreement to acquire the assets of PHC's Pivotal Research Centers.
buyer: Premier Research Group
Premier Research is a leading solutions-driven CRO committed to therapeutic focus and operational expertise to deliver clinical trial services of the highest quality for biopharmaceutical and medical device companies. "
target parent: Pioneer Behavioral Health
target: Pivotal Research Centers, LLC
Pivotal Research Centers, LLC provides clinical drug testing. It performs all phases of clinical research for Phase I to Phase IV drugs under development through two research sites. Pivotal was founded by Louis C. Kirby in 1993 and is based in Phoenix, Arizona.
price ($mm)
$3.00
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/30/2007 via Company Press Release

Chiltern International Inc., acquired Clinical Trial Management Services, Inc.

synopsis: Chiltern, a leading global clinical research organization (CRO), announced the acquisition of Clinical Trial Management Services, Inc. (CTMS) a Bristol, Tennessee based CRO offering high quality services throughout the United States.
buyer: Chiltern International Inc.
Chiltern is a global CRO with experience running and staffing international Phase I to Phase IV clinical trials. Chiltern’s services include: Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. "
target: Clinical Trial Management Services, Inc.
Clinical Trial Management Services, Inc. provides clinical research services such as clinical trial management and monitoring services, such as project management, investigative site management and monitoring services.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 12/14/2009 via BusinessWire

NexMed, Inc., acquired Bio-Quant, Inc.

synopsis: NexMed, Inc., a developer of products based on the NexACT® technology, announced the closing of its acquisition of Bio-Quant, Inc., a privately-held leading research organization for in vitro and in vivo contract drug discovery and pre-clinical development services, headquartered in San Diego, CA.
buyer: NexMed, Inc. (NEXM:$0.00)
NexMed is an innovative drug developer that is leveraging its proprietary NexACT® drug delivery technology to produce a host of new medical treatments. NexMed’s drugs address a variety of health conditions, such as nail fungus, sexual disorders and more. "
target: Bio-Quant, Inc.
Founded in 1999, Bio-Quant is the largest specialty CRO based in San Diego and is one of the industry's most experienced CROs for in vitro and in vivo pharmacology services and research models specializing in oncology, inflammation, immunology, and metabolic diseases, including diabetes.
price ($mm)[EV]
$13 [$13]
rev ($mm)
$5
EBITDA ($mm)
EV / rev
2.5x
EV / EBITDA
announced 10/28/2009 via PR Newswire

Alpha Analytical, will acquire Boston Analytical

synopsis: Alpha Analytical is announcing the completion of the acquisition of Boston Analytical, Inc. Established in 1987, Boston Analytical is a registered, cGMP compliant contract testing laboratory providing quality analytical and microbiological testing services to the pharmaceutical, biotech, device, cosmetic and nutritional product industries.
buyer: Alpha Analytical
Alpha Analytical, Inc. provides full-service environmental laboratory solutions for the most demanding industrial and commercial applications in the U.S. and abroad. Alpha Analytical is the largest environmental laboratory in New England and among the top 18 laboratories in the country. "
target: Boston Analytical
Boston Analytical is committed to providing quality Analytical and Microbiological testing services to pharmaceutical companies worldwide in support of their Product Development, Release and Stability Testing objectives.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 10/12/2009 via Company Press Release

J O Hambro Capital Management Limited, acquired Celsis International

synopsis: Chicago-based Celsis International, a leading global life sciences company, announces that it has been acquired by UK-based private equity firm J O Hambro and will de-list from the London Stock Exchange (LSE) and operate as a privately held company.
buyer: J O Hambro Capital Management Limited
J O Hambro Capital Management, the London-based boutique investment firm, offers an alternative to the large traditional fund management firms that have dominated the market for many years. "
target: Celsis International
Celsis International plc is a leading international provider of innovative life science products and laboratory services to the pharmaceutical and consumer products industries through our three divisions: Rapid Detection, Analytical Services and In Vitro Technologies.
price ($mm)[EV]
$55 [$52]*
rev ($mm)
$42
EBITDA ($mm)
$12
EV / rev
1.9x
EV / EBITDA
6.3x
closed 7/16/2009 via PR Newswire

Water Street Healthcare Partners, acquired AAIPharma Services

synopsis: Water Street Healthcare Partners, a leading private equity firm focused exclusively on the health care industry, announced that it has acquired the Pharmaceutical Development division from AAIPharma Inc.
buyer: Water Street Healthcare Partners
Water Street Healthcare Partners is a leading private equity firm focused exclusively on health care. With more than $1 billion of capital under management, Water Street is one of the most active investors in the health care industry. "
target parent: AAIPharma Inc.
target: AAIPharma Services
AAIPharma Services serves more than 300 large pharmaceutical and biotechnology companies. Its team of 450 scientists and professionals specialize in services that encompass the entire process of pharmaceutical drug development from discovery through commercialization.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
announced 6/1/2009 via Reuters

INC Research, Inc., will purchase Late Stage Research Unit from MDS, Inc.

synopsis: MDS Inc has announced that it planns to narrow its contract research focus by selling its late stage operations and central laboratory divisions to Contract Research Organization INC Research, Inc.
buyer: INC Research, Inc. (SYNH:$3,472.40)
INC Research is a therapeutically focused contract research organization with an unrivaled reputation for conducting Phase I- Phase IV clinical development programs of the highest integrity. "
seller: MDS, Inc. (MDZ:$231.00)
MDS Inc. is a global life sciences company that provides market-leading products and services that are used by its customers for the development of drugs, and the diagnosis and treatment of disease. The Company has more than 5,000 employees in 29 countries and net revenues of more than US$1.2 bil.
price ($mm)
$45
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA
closed 4/17/2009 via PR Newswire

ChemRar High-Tech Center, acquired Prudentas, LLC

synopsis: ChemDiv, a global chemistry-driven contract research organization, announced that its ChemRar High Tech Center has acquired Prudentas LLC, one of the leading CRO companies conducting high quality Phase I - Phase IV studies in Eastern Europe.
buyer parent: ChemDiv, Inc.
buyer: ChemRar High-Tech Center
The ChemRar High-Tech Center is a unique pharma and biotechnology complex founded by innovative life science organizations in Russia. ChemRar's component companies are engaged in discovering, developing and commercializing novel drugs for partners in Russia and worldwide. "
target: Prudentas, LLC
Prudentas is a Russian Clinical Contract Research Organization founded by and consisting of highly qualified clinical research professionals with extensive experience of working previously together as a team.
price ($mm)
rev ($mm)
EBITDA ($mm)
EV / rev
EV / EBITDA

Like Eidetics


read more

Eidetics

The Nielsen Company, Inc.

Medical Collective Intelligence Co. Ltd.

PharmARC Analytic Solutions Pvt. Ltd.

SDI Health LLC

SDI Health LLC

InforMed Direct

BioTrends Research Group, Inc.

Arlington Medical Resources Inc.

HHI Clinical Research & Statistical Services, L.L.C.

Newport Strategies, Inc.

Rapidata.net, Inc.

Double Helix

Rood Research, Inc.

Verispan, LLC

Information Resources, Inc.

Kalorama Information

Health Strategies Group

Metanexgen, Inc.

DoctorDirectory.com

read more

Eidetics

read more

Encore Health Resources

Quintiles Transnational Corp.

Encore Health Resources

VCG

Eidetics

read more

Invicro, LLC

Aptuit, Inc.

PAREXEL International Corporation

inVentiv Health, Inc.

Quintiles Transnational Corp.

Excel PharmaStudies Inc.

Encorium Group Inc.

Clinical Trials of the Americas, Inc.

Ockham Development Group, Inc.

AbCRO, Inc.

PharmaNet Development Group, Inc.

KAI Research, Inc.

Pivotal Research Centers, LLC

Clinical Trial Management Services, Inc.

Bio-Quant, Inc.

Boston Analytical

Celsis International

AAIPharma Services

MDS, Inc.

Prudentas, LLC

Geography
Matching Companies
Ticker: SYNH
 
 
 
 
 
 
 
 
INC Research, Inc.
INC Research, Inc.
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries.
year
2018
rev ($mm)
$3,472.40
EBITDA ($mm)
$441.82
EBIT ($mm)
$157.52
Net Income ($mm)
Employees
21000
  • drill down
  • watch
Ticker: ICLR
 
 
 
 
 
 
 
 
ICON Plc
ICON Plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development.
year
2015
rev ($mm)
$1,541.91
EBITDA ($mm)
$289.74
EBIT ($mm)
$234.82
Net Income ($mm)
$192.14
Employees
11200
  • drill down
  • watch
Ticker:
 
 
 
 
 
 
 
 
CMIC Co., Ltd.
CMIC is a leading full-service CRO in Japan offering a wide range of services in clinical trials in Asia to both multi-national and Japanese pharma companies.
year
2019
rev ($mm)
$664.65
EBITDA ($mm)
$76.21
EBIT ($mm)
$43.15
Net Income ($mm)
$23.12
Employees
4962
  • drill down
  • watch
Ticker: PIELF
 
 
 
 
 
 
 
 
Pierrel SpA
Pierrel SpA
Pierrel S.p.A. is a pharmaceutical company specializing in contract research, development and the manufacture of medicines. The Pierrel Group boasts over 50 years of experience in the pharmaceutical sector, and is one of the main Italian manufacturers of local anaesthetics for dental use.
year
2008
rev ($mm)
$64.38
EBITDA ($mm)
($4.23)
EBIT ($mm)
($8.92)
Net Income ($mm)
Employees
504
  • drill down
  • watch
Ticker: ENCO
 
 
 
 
 
 
 
 
Encorium Group Inc.
Encorium is a full-service Contract Research Organization providing comprehensive solutions for pharmaceutical, biotechnology, and medical device companies. At Encorium we recognize the challenges that often arise during drug development.
year
2008
rev ($mm)
$35.91
EBITDA ($mm)
($5.19)
EBIT ($mm)
($6.89)
Net Income ($mm)
Employees
226
  • drill down
  • watch
Ticker: ENXTPA:ERF
 
 
 
 
 
 
 
 
Eurofins Group
Eurofins Group
Based in Luxembourg, Eurofins is a leading international group of laboratories providing a unique range of analytical testing services to the pharmaceutical, food, environmental and consumer products industries and to governments.
year
2019
rev ($mm)
$5,244.00
EBITDA ($mm)
$922.65
EBIT ($mm)
$524.54
Net Income ($mm)
$224.34
Employees
47427
  • drill down
  • watch
Ticker: CRL
 
 
 
 
 
 
 
 
Charles River Laboratories International Inc.
Charles River Laboratories International Inc.
Charles River has been helping our global partners accelerate drug discovery and development by providing them with tailored research models and preclinical, clinical, support services.
year
2009
rev ($mm)
$1,202.55
EBITDA ($mm)
$282.48
EBIT ($mm)
$188.93
Net Income ($mm)
$114.44
Employees
8000
  • drill down
  • watch
Ticker: LH
 
 
 
 
 
 
 
 
LabCorp
LabCorp provides leading-edge medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp processes tests on approximately 470,000 specimens each day, applying advances in medicine and science to laboratory testing.
year
2009
rev ($mm)
$4,694.70
EBITDA ($mm)
$1,142.70
EBIT ($mm)
$949.40
Net Income ($mm)
$543.30
Employees
28000
  • drill down
  • watch